Depression and anxiety disorders during pegylated interferon treatment in patients with chronic hepatitis B

Basit Öğe Kaydı
dc.contributor.authorSertoz, Ozen Onen
dc.contributor.authorTuncel, Ozlem Kuman
dc.contributor.authorTasbakan, Meltem Isikgoz
dc.contributor.authorPullukcu, Husnu
dc.contributor.authorOnmus, Isabel Raika Durusoy
dc.contributor.authorYamazhan, Tansu
dc.contributor.authorElbi, Hayriye
dc.date.accessioned2019-10-27T11:21:55Z
dc.date.available2019-10-27T11:21:55Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectives: Interferon (IFN) treatment has many neuropsychiatric side effects such as depression and anxiety disorder. Although untreated depression is a major contributor to dosage reduction or premature discontinuation of the IFN treatment, it is found that depressive symptoms among patients undergoing hepatitis C virus (HCV) treatment are commonly overlooked during routine clinical interviews. Besides depression, anxiety disorders are shown to affect adherence to pegylated IFN (Peg-IFN) treatment in patients with hepatitis C. Despite the occurrence of neuropsychiatric side effects of IFN treatment being widely reported in patients with hepatitis C, there are few studies studying patients infected with hepatitis B virus (HBV). The aim of this prospective study was to evaluate the incidence and risk factors of depressive and anxiety disorders that occur during Peg-IFN treatment of patients with HBV. Methods: The sample consisted of volunteer patients who were diagnosed with HBV infection and who were decided to receive IFN treatment. During the study period, all consecutive patients with HBV infection and who would have IFN treatment were informed about the study and invited to participate. Thirty-seven chronic hepatitis B (CHB) patients were recruited for the study, but four of them were excluded due to psychiatric diagnosis at the initiation of the treatment. Therefore, the sample consisted of 33 patients with CHB, meeting the inclusion criteria. The participants had psychiatric assessment before the treatment and at 1st, 3rd, 6th, and 12th months. At each visit, the subjects were assessed with Clinical Global Impressions Scale, Hamilton Rating Scale for Depression (HRSD), and Hamilton Anxiety Rating Scale (HAM-A). Results: Among the 33 patients with HBV, 22 (66.7%) were men. Mean age was 35.97 +/- 10.73 years. While follow-up, 6 patients dropped out from the study. Also, 13 patients were excluded from the study as they developed depression and/or anxiety disorder. Mean baseline HRSD and HAM-A scores were smaller than the following visits' scores. The difference was not statistically significant only for the 12th month assessments. Totally 14 (42.4%) patients developed depression/anxiety disorder during 1 year follow-up. Six (42.86%) of them received the diagnosis at the 1st month, 3 (21.43%) at the 3rd, 4 (28.57%), at 6th months, and 1 (7.14%) at the 12th month. When we compared the patients who developed depression/anxiety disorder with the patients who did not develop any psychiatric disorder, we found that the mean baseline HRSD score (t = 2.303, p =.028) and female percentage (p =.017) were statistically significantly higher in the depression/anxiety disorder group. Conclusions: There is an incidence of 42.4% for depression and/or anxiety disorders during Peg-IFN treatment. Females and patients with subsyndromal depressive symptoms should be referred to a psychiatrist and closely monitored especially for the first three months of the IFN treatment.en_US
dc.identifier.doi10.1080/24750573.2017.1293251
dc.identifier.endpage53en_US
dc.identifier.issn2475-0573
dc.identifier.issn2475-0581
dc.identifier.issn2475-0573en_US
dc.identifier.issn2475-0581en_US
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage47en_US
dc.identifier.urihttps://doi.org/10.1080/24750573.2017.1293251
dc.identifier.urihttps://hdl.handle.net/11454/32975
dc.identifier.volume27en_US
dc.identifier.wosWOS:000401318800009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofPsychiatry and Clinical Psychopharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnxietyen_US
dc.subjectdepressionen_US
dc.subjecthepatitis Ben_US
dc.subjectinterferonen_US
dc.subjectpeginterferon alpha-2aen_US
dc.subjectpeginterferon alpha-2ben_US
dc.titleDepression and anxiety disorders during pegylated interferon treatment in patients with chronic hepatitis Ben_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu